RA Capital Management

Activity in this selectionOct 4, 2026 · Biotech · Jul 7, 2026

By stage

Series C+2

Series A1

Undisclosed1

Biotech4

United States4

4 in this selection

Aug 27

Develops oligonucleotide therapeutics targeting chronic hepatitis B

$120MSeries C

Role not disclosed

Aug 18

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries D

Role not disclosed

Aug 11

Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease

$75MSeries A

Role not disclosed

Aug 5

Develops fungal genome-derived therapeutics for organ transplant rejection

$263MSeries D+Series E

Role not disclosed